Cargando…
What failed BIA 10–2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials
Autores principales: | Kaur, Rimplejeet, Sidhu, Preeti, Singh, Surjit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020770/ https://www.ncbi.nlm.nih.gov/pubmed/27651707 http://dx.doi.org/10.4103/0976-500X.189661 |
Ejemplares similares
-
Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474
por: Bonifácio, Maria‐João, et al.
Publicado: (2020) -
Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase
por: Kiss, László E., et al.
Publicado: (2018) -
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10‐2474: A Double‐Blind, Randomized, Placebo‐Controlled Study in Healthy Volunteers
por: Rocha, José‐Francisco, et al.
Publicado: (2021) -
What Motivates Speculators to Speculate?
por: Gemeda, Bedane S., et al.
Publicado: (2019) -
2474. Emergence of Candida auris in Michigan
por: McNamara, Sara E, et al.
Publicado: (2023)